Abstract
The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Keywords: Alzheimer's disease, treatments, APOE genotype.
Current Pharmaceutical Design
Title:The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Volume: 21 Issue: 1
Author(s): Angela J. Hanson, Suzanne Craft and William A. Banks
Affiliation:
Keywords: Alzheimer's disease, treatments, APOE genotype.
Abstract: The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Export Options
About this article
Cite this article as:
Hanson Angela J., Craft Suzanne and Banks A. William, The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease, Current Pharmaceutical Design 2015; 21 (1) . https://dx.doi.org/10.2174/1381612820666141020164222
DOI https://dx.doi.org/10.2174/1381612820666141020164222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Editorial [Hot Topic: G-Protein-Coupled Receptors (GPCRs) and Drug Discovery (Guest Editor: Luca Gentilucci)]
Current Drug Targets Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation
Current Pharmaceutical Design Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design In vitro Antioxidant and Acetylcholinesterase Inhibitory Activities of Fractions from Centella asiatica (Linn.) Extract
Current Bioactive Compounds Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal Influence of Oxidative Stress on Catalytic and Non-glycolytic Functions of Glyceraldehyde-3-phosphate Dehydrogenase
Current Medicinal Chemistry Disruption of Calcium Homeostasis in the Pathogenesis of Alzheimers Disease and Other Conformational Diseases
Current Alzheimer Research Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Patent Selections
Recent Patents on Biotechnology Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology